$GKOS

Thurman Alex R. sold $1.5M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $150.00 ($1.50M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 9, 2026, 1:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($1.5M) and the fact it was executed under a pre-arranged 10b5-1 plan; this typically reduces interpretive weight.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional company news.

03

What to watch

The filing does not include any accompanying narrative, earnings context, or changes to corporate outlook, so traders should avoid over-weighting it versus fundamentals.

Relevance 5/10Novelty 3/10Timing: latest SEC Form 4 filed 2026-07-08 for a 2026-07-06 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp, listing the CFO as the reporting insider.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Form 4 shows GKOS CFO Thurman Alex sold 10,000 shares at $150 on 2026-07-06 under a 10b5-1 plan, worth $1.5M.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and it does not disclose new company fundamentals or guidance.

Market effects

No sector read-across; this is company-specific insider dealing.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view on GKOS.

Key entities

  • GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4.

  • Thurman Alex R.

    SVP and Chief Financial Officer who sold 10,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.